De-implementation of non cost-effective blood saving measures in total hip and knee replacement

Completed

• Conditions: implementation, blood management, total hip arthroplasty, total knee arthroplasty, behavior changeimplementatie, bloed management, totale heup arthroplastiek, totale knie arthroplastiek, gedragsverandering

• Registration Number: NL-OMON27165
• Lead Sponsor: eiden University Medical CenterP.O. Box 9600, 2300 RC Leiden, the Netherlands

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Hospitals using EPO and/or blood salvage in patients undergoing primary elective THA or TKA on a regular basis (more frequently than in exceptional cases)

- Hospitals performing at least 50 THA and/or TKA on average per 5 months.

Exclusion Criteria

- Hospitals considering to abandon the use of EPO or blood salvage on their own initiative

- Hospitals participating in trials that interfere with the use or the discontinuation of EPO or blood salvage

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome is the % of patients undergoing primary elective total hip or knee arthroplasty in which EPO or blood salvage is applied.

Secondary Outcome Measures

Name	Time	Method
Secondary study parameters are the patient outcomes of the surgery including post-operative hemoglobin (Hb) level, length of hospital stay and number of allogeneic transfusions. Also possible complications will be registered: reactions on EPO use, transfusion reactions due to the use of blood salvage, transfusion reactions due to allogeneic transfusions, other (serious) adverse events.